Pyxis Oncology, Inc. (PYXS) financial statements and ratios from SEC XBRL: revenue $13.86M (TTM), net margin -574.5%, revenue growth -97.8% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $13.86M |
| Net Margin | -574.5% |
| Revenue Growth (YoY) | -97.8% |
| EPS Growth (YoY) | 33.3% |
| Price / Book | 22.38 |
| Price / Sales | 346.50 |
| FCF Yield | -20.7% |
| Altman Z-Score | -5.97 (distress) |
| Sector P/E (Healthcare) | 21.7 |
PYXS overview · PYXS earnings · PYXS KPIs · PYXS investor relations · PYXS ownership · PYXS peers · PYXS filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.